Blood Screening Market Size Worth $3.9 Billion By 2024 | CAGR 10.2%: Grand View Research, Inc.

SAN FRANCISCO, May 7, 2018 /PRNewswire/ --

The global blood screening market [https://www.grandviewresearch.com/industry-analysis/blood-screening-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May07_Blood_Screening_RD1&utm_content=Content ]  is expected to reach a value of USD 3.9 billion by 2024, based on a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Browse full research report with TOC on "Blood Screening Market Size, Share & Trends Analysis Report By Product (Reagent, Instrument), By Technology (NAT, ELISA, CLIA & EIA, NGS, Western Blotting), By Region, And Segment Forecasts, 2018 - 2024" at: https://www.grandviewresearch.com/industry-analysis/blood-screening-market [https://www.grandviewresearch.com/industry-analysis/blood-screening-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May07_Blood_Screening_RD2&utm_content=Content ]

Further Key Findings From the Report Suggest: 

        
        - Nucleic acid amplification test or nucleic acid test (NAT) is expected to be the
          fastest growing segment during the forecast period. It comprises transcription
          mediated amplification (TMA) tests and polymerase chain reaction. Increasing demand of
          NAT over ELISA test due to high sensitivity and specificity for viral nucleic acid is
          contributing to the fastest growth during the forecast period. The American Red Cross
          implemented automated triplex NAT for HCV, HIV, and HBV in 2009. This would further
          boost the industry.
        - In 2015, reagent dominated the product segment. Introduction of new assays for the
          detection of various diseases is expected to enable the segment to gain the maximum
          share in the coming years. For instance, in January 2015 the FDA approved Roche's
          blood screening assay COBAS TaqScreen MPX Test for the detection and identification of
          HCV, HIV, and HBV.
        - In 2015, regionally North America dominated with a revenue share of more than 40%.
          Government initiatives, presence of major players, and more patient affordability are
          the major factors that contributed toward its dominance. The U.S. FDA strengthens
          regulations that protect patients from unsuitable products.
        - Recently, the FDA published a guidance document proposing regulations for laboratory
          developed tests. In addition, In February 2015, the U.S. FDA conducted a workshop to
          discuss the oversight of NGS. All these factors increase awareness, which would
          further increase the growth of the industry.
        - In August 2016, the FDA recommended the testing of all the donated blood in the U.S.
          and its territories for Zika virus in order to prevent transmission of this virus
          through the blood supply.
        - Asia Pacific is expected to be the fastest growing region due to increasing investment
          of industry players, government initiatives, and rising awareness about transmission
          of diseases during its transfusion.
        - The Red Cross in Japan entered into a contract with Grifols for nucleic acid testing
          (NAT) for a donation camp in Japan in 2014. This agreement is anticipated to propel
          the NAT during the forecast period. However, low donation as compared to requirement
          and high cost of kits and instruments are likely to restrain the growth in low-income
          countries during the forecast period.
        - In June 2015, India launched a National Blood Donor Vigilance Programme (NBDVP) to
          undertake donor vigilance activity. Such initiatives from emerging countries improve
          the donor safety and satisfaction and thereby drives the market in coming years.
        - Some of the players operating in the industry are Abbott Laboratories; Danaher
          Corporation (Beckman Coulter); Becton Dickinson and Company; Bio-Rad Laboratories,
          Inc.; F. Hoffmann-La Roche Ltd.; Grifols; Ortho-Clinical Diagnostics, Inc.; Siemens
          AG; and Thermo Fisher Scientific. Partnerships and acquisitions play an important role
          in capturing the market. Competition between the industry players is rigorous due to
          the presence of advanced instruments and assays.

Browse related reports by Grand View Research: 

        
        - Lymphoma Market
          [https://www.grandviewresearch.com/industry-analysis/lymphoma-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May07_Blood_Screening_RL1&utm_content=Content ]
          - Lymphoma is a medical term for blood cancer. Development of lymphoma indicates 
          abnormal growth of B or T lymphocytes and also if these cells survive longer than
          their normal cycle.
        - Autoimmune Disease Diagnostics Market
          [https://www.grandviewresearch.com/industry-analysis/autoimmune-disease-diagnostics-industry?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May07_Blood_Screening_RL2&utm_content=Content ]
           - The global Autoimmune Disease Diagnostics Market 
          disease diagnostics market size was valued at USD 3.3 billion in the year 2015 and is
          estimated to reach a value of USD 5.0 billion by 2025.
        - Nucleic Acid Amplification Testing Market
          [https://www.grandviewresearch.com/industry-analysis/nucleic-acid-amplification-testing-naat-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May07_Blood_Screening_RL3&utm_content=Content ]
          - The global nucleic acid amplification testing 
          (NAAT) market size was valued at USD 1.78 billion in 2015. 
        - Kidney Function Tests Market
          [https://www.grandviewresearch.com/industry-analysis/kidney-function-tests-market?utm_source=pressrelease&utm_medium=referral&utm_campaign=PRN_May07_Blood_Screening_RL4&utm_content=Content ]
          - The global kidney function tests market size was valued at USD 
          1.2 billion in 2016 and is expected to grow at a CAGR of 5.2% over the forecast
          period.

Grand View Research has segmented the blood screening market by product, technology, and region: 

        
        - Blood Screening Technology Outlook (Market Revenue in USD Million, 2013 - 2024) 
             - Nucleic Acid Amplification Test (NAT)
             - ELISA
             - Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
             - Next-Generation Sequencing (NGS)
             - Western Blotting
        - Blood Screening Product Outlook (Market Revenue in USD Million, 2013 - 2024) 
             - Reagent
             - Instrument
        - Blood Screening Regional Outlook (Market Revenue in USD Million, 2013 - 2024) 
             - North America
                - U.S.
                - Canada
             - Europe
                - UK
                - Germany
             - Asia Pacific
                - Japan
                - China
             - Latin America
                - Brazil
             - Middle East and Africa
                - South Africa

Rad Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

        

        Contact: 
        Sherry James 
        Corporate Sales Specialist, USA 
        Grand View Research, Inc 
        Phone: +1-415-349-0058 
        Toll Free: 1-888-202-9519 
        Email: sales@grandviewresearch.com 

 

Web: https://www.grandviewresearch.com


    Photo: 
    https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg


SOURCE Grand View Research, Inc.